Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus
Article first published online: 2 JUL 2013
© 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing Asia Pty Ltd
International Journal of Rheumatic Diseases
Volume 16, Issue 4, pages 408–412, August 2013
How to Cite
Zhang, X., Zhang, F., Wu, D., Bao, C., Zhu, P., Zhang, X., Huang, C., He, D., Tao, Y., Fang, Y., Gu, J., Wu, H., Sun, L., Yang, X., Huang, F., Xu, H., Zhao, D., Zhang, M., Zheng, Y. and Li, Z. (2013), Safety of infliximab therapy in rheumatoid arthritis patients with previous exposure to hepatitis B virus. International Journal of Rheumatic Diseases, 16: 408–412. doi: 10.1111/1756-185X.12125
- Issue published online: 31 AUG 2013
- Article first published online: 2 JUL 2013
- HBV infection;
- rheumatoid arthritis
To evaluate the safety of tumor necrosis factor-α (TNF-α) monoclonal antibody (infliximab) therapy in patients with rheumatoid arthritis (RA) and previous exposure to hepatitis B virus (HBV) who had normal liver function.
This is a retrospective study from a 26-week, prospective, multicenter trial in 234 patients with RA who received infusions of infliximab (3 mg/kg at week 0, 2, 6, 14 and 22). The medical records of these patients were reviewed, including the information on disease duration, laboratory tests and HBV markers. The data on liver function during the study was analyzed, as well as comparison between patients with previous exposure to HBV and patients without such exposure.
Forty-one patients with previous exposure to HBV were HBsAg(-). Forty patients had normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and only one patient with positive anti-HBc showed an elevated ALT level before administration of infliximab, and had a further increase of ALT level at week 14, but decreased thereafter. The average ALT and AST levels rose slightly during the treatment but remained in normal range and the differences were insignificant compared with baseline. There was no statistically significant difference in the incidence of liver function abnormalities during the treatment of infliximab between the patients with previous exposure to HBV and those without such exposure.
In patients with RA and previous exposure to HBV but with a negative HBsAg and normal liver function at baseline, liver function abnormalities were not observed during infliximab treatment.